Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai’s Corporate VC Arm to Go Live in 2024
December 20, 2023
- Daiichi Sankyo Launch 2 PIII Breast Cancer Trials for TROP2 ADC
December 20, 2023
- Xocova Rights Sub-Licensed to Juniper in Singapore: Shionogi
December 20, 2023
- Otsuka Bags European Commercial Rights to Ionis’ HAE Drug
December 20, 2023
- Ono, EVQLV Link Arms on AI-Powered Antibody Drug Development
December 20, 2023
- Sanofi Files High-Dose Quadrivalent Flu Vaccine in Japan
December 20, 2023
- DyDo Pharma Files Its 1st Drug, LEMS Treatment for Japan Market
December 19, 2023
- EMA Endorses GHIT-Funded Schistosomiasis Therapy
December 19, 2023
- Dupixent 200 mg Syringe Now Available in Japan: Sanofi
December 19, 2023
- Shionogi, Sobi Ink Fetcroja Distribution Pact for 13 European Countries
December 19, 2023
- Shionogi Kicks Off PIII Booster Trial for XBB1.5 COVID Vaccine in Japan
December 19, 2023
- Takeda’s Hyqvia Gets EU Panel Backing for CIDP Maintenance Therapy
December 19, 2023
- Padcev/Keytruda Combo Nabs FDA Nod for 1st Line Bladder Cancer
December 19, 2023
- Eisai Files Tasurgratinib for Biliary Tract Cancer in Japan
December 19, 2023
- Terumo’s Next CEO Resolved to Drive Biologics Forward, Fulfill Diverse Demands
December 18, 2023
- Eisai CEO Anticipates Leqembi Approval in Europe and China by March
December 18, 2023
- Alecensa Filed for Adjuvant Therapy for ALK-Positive NSCLC: Chugai
December 18, 2023
- Cheplapharm Initiates LLP Acquisitions in Japan, Eyes 10 Asset Takeovers in 2024: Local Head
December 15, 2023
- Taisho Aims to Make “Alli” 5th Leg of Its Consumer Healthcare Biz, Eyes Annual Sales of 2-3 Billion Yen
December 15, 2023
- JCR Bags FDA’s Orphan Tag for MPS IIIA Drug in US
December 15, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…